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Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital disorder characterized by skin lesions, neurosensorial hypoa-
cusia, and keratitis, usually due to the c.148G → A mutation involving the connexin 26 gene. We report on a KID patient who
showed the atypical c.101T → C mutation and developed a T-cell lymphoma so far never described in this group of patients.
1. Introduction
Keratitis-ichthyosis-deafness (KID) syndrome is a rare con-
genital disorder characterized by a variety of skin lesions—
that is, palmoplantar keratoderma, thickening of the
skin, and erythematous verrucous lesions—neurosensorial
hypoacusia, and keratitis with a variable degree of visual
impairment [1]. Both sporadic and familial forms of the
syndrome have been described, the latter usually showing a
dominant pattern of inheritance [2]. The molecular lesion
responsible for the syndrome typically involves the connexin
26 (Cx26) gene (GJB2). Most patients display the heterozy-
gous c.148G→A mutation causing the substitution of an
aspartic acid for an asparagine at position 50 (p.Asp50Asn),
while a few of them show the c.50C→T mutation, implying
the substitution of a serine for a phenylalanine at position 17
(p.Ser17Phe) [2]. However, even a mutation in the connexin
30 (Cx30) gene (GJB6) has been found in a typical KID
patient [3], thus suggesting a genetic heterogeneity of the
syndrome. As connexins are a large family of small integral
membrane proteins which influence tissue cornification by
modulating the establishment of direct cell-cell communica-
tion through gap junction channels [4], it is likely that defects
involving this class of proteins are at the basis of the well-
known increased incidence of squamous cell carcinoma in
KID patients [5].
2. Case Presentation
Here we report on an adult patient with a typical KID
syndrome who developed a peripheral T-cell lymphoma. It
is worth noting that sequencing of GJB2 and GJB6 genes
revealed only a Cx26 (GJB2) c.101T→C mutation, a variant
usually associated with isolated hearing impairment [6, 7].
Briefly, the patient presented skin ichthyosis since his
adolescence and in subsequent years developed severe
bilateral hypoacusia and keratitis. The coexistence of such
progressively worsening features pointed to the clinical
diagnosis of KID syndrome. At that time, no molecular
investigations were performed. The patient came to our
attention in November 2007, when he was 65 years old,
with diﬀuse lymphoadenopathy and splenomegaly (122mm)
associated to thrombocytopenia (84 × 109/L), neutropenia
(1.4 × 109/L), and elevated lactate dehydrogenase level
(1578U/L) along with a worsening of his erythemato-
sus desquamating cutaneous rash. After an inguinal node
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Figure 1: A search for mutations within the connexin 26 gene GJB2 showed the heterozygous c.101T→C mutation (in red in the figure)
causing the substitution of a methionine residue for threonine at position 34 (p.Met34Thr).
Table 1: GJB2 forward and reverse primers.
GJB2 FW F1 CATTCGTCTTTTCCAGAGCA
GJB2 RV F1 CACGTGCATGGCCACTAG
GJB2 FW F2 CGTGTGCTACGATCACTAC
GJB2 RV F2 AGCCTTCGATGCGGACCTT
GJB2 FW F3 ACCGGAGACATGAGAAGAAG
GJB2 RV F3 TTCCAGACACTGCAATCATG
GJB2 FW F4 TATGTCATGTACGACGGCT
GJB2 RV F4 TCTAACAACTGGGCAATGC
biopsy, a diagnosis of CD3+, CD45RO+, bcl2+, and CD7+
peripheral T-cell non-Hodgkin lymphoma (NHL) wasmade.
Because of bone marrow involvement in trephine biopsy,
the lymphoma stage resulted to be IV A with a high risk
on the International Prognostic Index (IPI). Besides an
infiltration by T-lymphoma cells, the skin biopsy showed
epidermal cysts, hyperkeratotic lesions, and inflammatory
nodules. The ophttalmoscopic and audiometric evaluations
showed bilateral neurosensorial hypoacusia and superficial
punctate keratitis. All these findings being compatible with
a fully expressed KID phenotype, the GJB2 gene sequencing
was firstly performed. Briefly, after genomic DNA extraction
from peripheral blood following the standard salting-out
procedures, GJB2 was amplified by PCR using the primers
reported in Table 1. PCR products were then sequenced
on an ABI Prism 3130 genetic analyzer by using BigDye
Terminator v3.1 (Applied Biosystems) showing the het-
erozygous c.101T→C mutation (Figure 1), which causes
the substitution of a methionine residue for threonine at
position 34 (p.Met34Thr, briefly M34T). Both the GJB2
c.148G→A and c.50C→T gene mutations usually found to
be associated with KID syndrome [2] were excluded. The
sequencing analysis was then extended to the Cx30 GJB6
coding gene but failed to reveal any further mutation.
Our patient was treated with a combination of chem-
otherapy including Cyclophosphamide, Doxorubicin, Vin-
cristine, and Prednisone and immunotherapy with Alem-
tuzumab. After a partial response, the patient died of
Cytomegalovirus pneumonia 7 months after the diagnosis of
T-cell lymphoma.
3. Discussion
The present case deserves some comments. Firstly, the M34T
mutation causing the substitution of a methionine residue
for threonine at position 34 (p.Met34Thr) has never been
described in patients with typical KID syndrome, whereas
it has already been found in a homozygous as well as in a
double heterozygous state in subjects with isolated hearing
impairment. However, even in these cohorts this mutation
was reported with extremely low frequencies [6, 7]. In
addition, as the M34T variant has an allele frequency of
about 1% even the in the whole European healthy population
[8], we ought to conclude that the pathogenetic role of the
M34T variant in our KID patient has still to be proved.
Secondly, an increased susceptibility to cutaneous cancer
has been reported in subjects with KID syndrome [5].
Considering that the CX26 gene modulates the cadherin
expression [9], it is probable that such a susceptibility may
be related to the cadherin downregulation described in
approximately 70% of squamous cell carcinoma patients
[10]. On the other hand T-cell NHLs are rare malignancies
accounting for 10% to 15% of all NHLs [11]. Cadherin
is expressed and functionally active even in T-lymphoma
cells, implying a possible involvement in the mechanisms of
lymphoma cell dissemination to skin and central nervous
system [12]. Therefore, the coexistence of KID syndrome
and T-cell lymphoma may be more than a coincidence. In
the same way as the gene sequencing of GJB2 and GJB6,
with the exception of the M34T variant, did not reveal
any of the molecular defects typical of KID syndrome, we
are tempted to conclude that such an association of three
extremely rare conditions in the same patient might not be
merely accidental.
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